Suppliers / Yangzhou Aurisco Pharmaceutical

Yangzhou Aurisco Pharmaceutical

China 1 employees Updated 9 July 2026

Yangzhou Aurisco Pharmaceutical is an API manufacturer based in China. It holds 18 active US drug master files and 2 valid CEPs across a filed portfolio of 16 molecules.

18
active US DMFs
2
valid CEPs
2
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026.

Registered plants

Site FDA FEI
Yangzhou City, China Not on file
China, China 3021695089

What they file, and where

Molecule Regulators Docs
Medroxyprogesterone Acetate SFDA (Saudi Arabia), US FDA 4
Bempedoic Acid SFDA (Saudi Arabia), US FDA 3
Brivaracetam EDQM, US FDA 3
Semaglutide US FDA 2
Clascoterone US FDA 1
Dydrogesterone EDQM 1
Elagolix US FDA 1
Estetrol US FDA 1
Estradiol US FDA 1
Inclisiran US FDA 1
Show all 16 molecules on file
Nusinersen US FDA 1
Rimegepant US FDA 1
Tenofovir Disoproxil US FDA 1
Tirzepatide US FDA 1
Vibegron US FDA 1
Vutrisiran US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
JFDA (JO) 1 None

Comparing suppliers?

Choose your molecules and target markets. Yangzhou Aurisco Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability